Clinical Trials · NCT04961996
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 4,170
- Start date
- Aug 2021
- Locations
- 622 sites, 54 countries
- Primary endpoint
- Invasive Disease-Free Survival (IDFS), Excluding Second Primary Non-Breast Cancers